Korro Bio, Inc. (KRRO) SEC filings

KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$13.61−0.70 (-4.89%)

Close on Nov 13, 2026Market cap $200.42MP/E –Yield –

SEC filings

40 of Korro Bio's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 3, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 22, 2026	Oct 22, 2026	SEC EDGAR
Current report	8-K	Oct 5, 2026	Oct 5, 2026	SEC EDGAR
Current report	8-K	Aug 19, 2026	Aug 19, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 19, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 10, 2026	Apr 16, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Current report	8-K	Jan 27, 2026	Jan 27, 2026	SEC EDGAR
Current report	8-K	Jan 15, 2026	Jan 15, 2026	SEC EDGAR
Current report	8-K	Dec 15, 2025	Dec 18, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 7, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 7, 2025	Oct 8, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 11, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 27, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 18, 2025	SEC EDGAR
Current report	8-K	Mar 18, 2025	Mar 18, 2025	SEC EDGAR
Current report	8-K	Feb 11, 2025	Feb 11, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Current report	8-K	Nov 21, 2024	Nov 21, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 4, 2024	Nov 4, 2024	SEC EDGAR
Current report	8-K	Sep 13, 2024	Sep 16, 2024	SEC EDGAR
Current report	8-K	Aug 26, 2024	Aug 28, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 13, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Korro Bio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-130 reverse split on Mar 26, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KRRO.

Compare: KRRO vs NGNE · KRRO vs SLN · KRRO vs TRDA · KRRO vs OVID · KRRO vs RNAC

Revenue growth-82.5% · median -93.5%

Operating margin-8467.3% · median -7903.6%

Net margin-8214.5% · median -6903.2%

Company	Revenue	Growth
TRDA	$3.98M	-93.5%
OVID	$1.45M	-78.0%
KRRO	$1.29M	-82.5%
RNAC	$1.03M	–
SLN	$615.00K	-97.7%
NGNE	–	–

Company

Next earnings (est.): Mar 11, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 58
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1703647

Advertisement
300 × 250

See a number that looks wrong?